research A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.
Search
for
Sort by
Research
990-1000 / 1000+ results research Predictive Factors of Response and Real‐World Experience of Baricitinib on Alopecia Areata: A Single Tertiary Center Study on a 72 Patients' Cohort
Baricitinib is a safe and effective treatment for alopecia areata, with better results in patients with lower initial severity, shorter disease duration, and longer treatment.
research Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
research Gene Array Profiling and Immunomodulation Studies Define a Cell-Mediated Immune Response Underlying the Pathogenesis of Alopecia Areata in a Mouse Model and Humans
Alopecia areata is caused by an immune response, and targeting immune cells might help treat it.
research An Extended Epidermal Response Heals Cutaneous Wounds in the Absence of a Hair Follicle Stem Cell Contribution
Skin can heal wounds without hair follicle stem cells, but it takes a bit longer.
research The Cutaneous Inflammatory Response to Thermal Burn Injury in a Murine Model
Burn injuries in mice heal similarly to humans, with inflammation and cell changes normalizing over time.
research Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease‐associated psychological morbidity
Alopecia areata involves immune system imbalances that may lead to depression and anxiety.
research Fractional Photothermolysis Laser Treatment of Male Pattern Hair Loss
Laser treatment can stimulate hair growth for male pattern hair loss.
research Targeting Cutaneous Cannabinoid Signaling in Inflammation - A “High”-way to Heal?
Enhancing cannabinoid signaling may help treat skin inflammation.
research Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C
Vogt-Koyanagi-Harada disease can develop during interferon therapy for chronic hepatitis C.